Fig. 2: Conceptualising the continuum of the metabolic syndrome and MASH within hepatology practice. | npj Gut and Liver

Fig. 2: Conceptualising the continuum of the metabolic syndrome and MASH within hepatology practice.

From: Reviewing MAESTRO-NASH and the implications for hepatology and health systems in implementation/accessibility of Resmetirom

Fig. 2

ACEi Angiotensin-Converting Enzyme Inhibitors, ARBs Angiotensin II Receptor Blockers, B-blockers Beta blockers, CCB Calcium Channel Blockers, DPP4i Dipeptidyl Peptidase-4 Inhibitor; GcG Glucagon; GIP Gastric Inhibitory Polypeptide, GLP-1RA Glucagon-Like Peptide-1 Receptor Agonists, MRA Mineralocorticoid Receptor Antagonists, SGLT-2i Sodium-Glucose Cotransporter 2 Inhibitor.

Back to article page